In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA Issues Warning: Compounding Certain Bulk Drug Substances May Pose Major Legal and Patient Safety Risks Lengea BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & What Is BPC 157? A Medical Clinic's Guide to the Body Protective Peptide, Its Uses, and What It Actually Does Perfect B The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and